{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T06:33:43Z","timestamp":1793082823523,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the American Society of Hypertension"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.jash.2013.12.001","type":"journal-article","created":{"date-parts":[[2013,12,5]],"date-time":"2013-12-05T00:46:22Z","timestamp":1386204382000},"page":"146-151","source":"Crossref","is-referenced-by-count":23,"title":["Modulation of aldosterone levels by \u2212344\u00a0C\/T CYP11B2 polymorphism and spironolactone use in resistant hypertension"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0146-9113","authenticated-orcid":false,"given":"Vanessa","family":"Fontana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8585-7238","authenticated-orcid":false,"given":"Ana Paula Cabral","family":"de Faria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1596-1085","authenticated-orcid":false,"given":"Nat\u00e1lia Ruggeri","family":"Barbaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3338-2845","authenticated-orcid":false,"given":"Andr\u00e9a Rodrigues","family":"Sabbatini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Modolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3738-2036","authenticated-orcid":false,"given":"Riccardo","family":"Lacchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6330-697X","authenticated-orcid":false,"given":"Heitor","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jash.2013.12.001_bib1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.tem.2012.09.004","article-title":"Aldosterone and cardiovascular disease: the heart of the matter","volume":"24","author":"He","year":"2013","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.jash.2013.12.001_bib2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.amjcard.2006.01.059","article-title":"Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease","volume":"98","author":"Ferrario","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jash.2013.12.001_bib3","doi-asserted-by":"crossref","first-page":"776","DOI":"10.7326\/0003-4819-150-11-200906020-00005","article-title":"Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension","volume":"150","author":"Sowers","year":"2009","journal-title":"Ann Int Med"},{"key":"10.1016\/j.jash.2013.12.001_bib4","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa033263","article-title":"Serum aldosterone and the incidence of hypertension in nonhypertensive persons","volume":"351","author":"Vasan","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jash.2013.12.001_bib5","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/S0895-7061(97)00301-4","article-title":"Association between increased plasma levels of aldosterone and decreased systemic arterial compliance in subjects with essential hypertension","volume":"10","author":"Blacher","year":"1997","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.jash.2013.12.001_bib6","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/hr.2013.92","article-title":"Hypoadiponectinemia and aldosterone excess are associated with lack of blood pressure control in subjects with resistant hypertension","volume":"36","author":"de Faria","year":"2013","journal-title":"Hypertens Res"},{"key":"10.1016\/j.jash.2013.12.001_bib7","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1161\/HYPERTENSIONAHA.108.189141","article-title":"Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research","volume":"51","author":"Calhoun","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.jash.2013.12.001_bib8","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1001\/archinte.168.11.1159","article-title":"Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion","volume":"168","author":"Gaddam","year":"2008","journal-title":"Arch Int Med"},{"key":"10.1016\/j.jash.2013.12.001_bib9","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1161\/HYPERTENSIONAHA.109.140988","article-title":"Efficacy of spironolactone therapy in patients with true resistant hypertension","volume":"55","author":"de Souza","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.jash.2013.12.001_bib10","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1751-7176.2009.00110.x","article-title":"Aldosterone excess or escape: Treating resistant hypertension","volume":"11","author":"Ubaid-Girioli","year":"2009","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.jash.2013.12.001_bib11","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/hr.2012.43","article-title":"Reevaluation of the association of seven candidate genes with blood pressure and hypertension: a replication study and meta-analysis with a larger sample size","volume":"35","author":"Takeuchi","year":"2012","journal-title":"Hypertens Res"},{"key":"10.1016\/j.jash.2013.12.001_bib12","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/01.hjh.0000254372.88488.a9","article-title":"Association of the C-344T aldosterone synthase gene variant with essential hypertension: a meta-analysis","volume":"25","author":"Sookoian","year":"2007","journal-title":"J Hypertens"},{"key":"10.1016\/j.jash.2013.12.001_bib13","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1161\/01.HYP.33.2.703","article-title":"Aldosterone excretion rate and blood pressure in essential hypertension are related to polymorphic differences in the aldosterone synthase gene CYP11B2","volume":"33","author":"Davies","year":"1999","journal-title":"Hypertension"},{"key":"10.1016\/j.jash.2013.12.001_bib14","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1161\/HYPERTENSIONAHA.112.200741","article-title":"Common polymorphisms in the CYP11B1 and CYP11B2 genes: evidence for a digenic influence on hypertension","volume":"61","author":"Alvarez-Madrazo","year":"2013","journal-title":"Hypertension"},{"key":"10.1016\/j.jash.2013.12.001_bib15","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1055\/s-2002-23491","article-title":"Ratio of serum aldosterone to plasma renin concentration in essential hypertension and primary aldosteronism","volume":"110","author":"Trenkel","year":"2002","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1016\/j.jash.2013.12.001_bib16","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.amjcard.2009.12.017","article-title":"Characteristics and predictors of obstructive sleep apnea in patients with systemic hypertension","volume":"105","author":"Drager","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jash.2013.12.001_bib17","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.amjhyper.2004.12.005","article-title":"Clinical and genetic correlates of serum aldosterone in the community: the Framingham Heart Study","volume":"18","author":"Kathiresan","year":"2005","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.jash.2013.12.001_bib18","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/hr.2008.36","article-title":"T allele of -344 C\/T polymorphism in aldosterone synthase gene is not associated with resistant hypertension","volume":"32","author":"Lacchini","year":"2009","journal-title":"Hypertens Res"},{"key":"10.1016\/j.jash.2013.12.001_bib19","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1097\/00004872-200410000-00011","article-title":"Aldosterone synthase gene (CYP11B2) C-344T polymorphism, plasma aldosterone, renin activity and blood pressure in a multi-ethnic population","volume":"22","author":"Barbato","year":"2004","journal-title":"J Hypertens"},{"key":"10.1016\/j.jash.2013.12.001_bib20","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1677\/jme.0.0280125","article-title":"Differential regulation of aldosterone synthase and 11beta-hydroxylase transcription by steroidogenic factor-1","volume":"28","author":"Bassett","year":"2002","journal-title":"J Mol Endocrinol"},{"key":"10.1016\/j.jash.2013.12.001_bib21","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3109\/08037051.2011.617045","article-title":"Vascular stiffness and endothelial dysfunction: Correlations at different levels of blood pressure","volume":"21","author":"Figueiredo","year":"2012","journal-title":"Blood Press"},{"key":"10.1016\/j.jash.2013.12.001_bib22","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/jhh.2010.95","article-title":"Characteristics of resistant hypertension: ageing, body mass index, hyperaldosteronism, cardiac hypertrophy and vascular stiffness","volume":"25","author":"Martins","year":"2011","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.jash.2013.12.001_bib23","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/jhh.2012.29","article-title":"High-circulating leptin levels are associated with increased blood pressure in uncontrolled resistant hypertension","volume":"27","author":"de Haro Moraes","year":"2013","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.jash.2013.12.001_bib24","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1161\/01.HYP.0000040261.30455.B6","article-title":"Hyperaldosteronism among black and white subjects with resistant hypertension","volume":"40","author":"Calhoun","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.jash.2013.12.001_bib25","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1161\/HYPERTENSIONAHA.107.100701","article-title":"Relation of dietary salt and aldosterone to urinary protein excretion in subjects with resistant hypertension","volume":"51","author":"Pimenta","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.jash.2013.12.001_bib26","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0895-7061(03)01032-X","article-title":"Efficacy of low-dose spironolactone in subjects with resistant hypertension","volume":"16","author":"Nishizaka","year":"2003","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.jash.2013.12.001_bib27","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/ncpneph0575","article-title":"The incidence and implications of aldosterone breakthrough","volume":"3","author":"Bomback","year":"2007","journal-title":"Nat Clin Pract Nephrol"},{"key":"10.1016\/j.jash.2013.12.001_bib28","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1161\/01.HYP.0000067463.13172.EA","article-title":"Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension","volume":"41","author":"White","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.jash.2013.12.001_bib29","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1038\/nm.2891","article-title":"Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors","volume":"18","author":"McCurley","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.jash.2013.12.001_bib30","doi-asserted-by":"crossref","first-page":"C532","DOI":"10.1152\/ajpcell.00203.2012","article-title":"Aldosterone mediates its rapid effects in vascular endothelial cells through GPER activation","volume":"304","author":"Gros","year":"2013","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.jash.2013.12.001_bib31","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1161\/HYPERTENSIONAHA.110.161653","article-title":"GPR30 expression is required for the mineralocorticoid receptor-independent rapid vascular effects of aldosterone","volume":"57","author":"Gros","year":"2011","journal-title":"Hypertension"}],"container-title":["Journal of the American Society of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933171113002052?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933171113002052?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,8]],"date-time":"2018-10-08T10:22:47Z","timestamp":1538994167000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933171113002052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S1933171113002052"],"URL":"https:\/\/doi.org\/10.1016\/j.jash.2013.12.001","relation":{},"ISSN":["1933-1711"],"issn-type":[{"value":"1933-1711","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]}}}